Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03772-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Takanori Teshima und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. teshima@med.hokudai.ac.jp. Hauptthemen laut MEDLINE: Nitriles, Pyrazoles, Pyrimidines, Graft vs Host Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.
Abstract (Originalsprache)
Acute graft-versus-host disease (aGvHD) is a major complication after allogeneic hematopoietic stem cell transplantation in Japan and other countries. Nearly one-third of patients do not respond to standard systemic steroid therapy and no standard second-line treatment has been established in Japan. We report efficacy and safety findings of ruxolitinib versus best available therapy (BAT) from a subgroup analysis of the international, phase 3 REACH2 study in Japanese patients with steroid-refractory aGvHD. The primary endpoint was overall response rate (ORR) at day 28. Overall, 9 patients received ruxolitinib and 21 received BAT. The ORR at day 28 (88.9% vs 52.4%) and durable ORR at day 56 (66.7% vs 28.6%) were higher with ruxolitinib versus BAT. The estimated cumulative incidence of loss of response at 6 months was 12.5% with ruxolitinib and 18.2% with BAT. The median failure-free survival was longer with ruxolitinib versus BAT (2.73 vs 1.25 months). The most common adverse events up to day 28 in the ruxolitinib and BAT groups were anemia (55.6% vs 19.0%) and thrombocytopenia (44.4% vs 4.8%, respectively). Ruxolitinib showed better efficacy outcomes and a consistent safety profile compared with BAT in the Japanese subgroup, and the findings were consistent with overall study results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. teshima@med.hokudai.ac.jp.
- Department of Hematology, Tohoku University Hospital, Sendai, Japan.
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
- Department of Hematology, Toranomon Hospital, Tokyo, Japan.
- Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
- Inuyama Chuo General Hospital, Inuyama, Japan.
Förderung
- Novartis
Zitieren
APA
Teshima, T., Onishi, Y., Kato, K., Taniguchi, S., Miyamura, K., Fukushima, K., Kato, J., Ishikawa, T., Doki, N., Nakamae, H., Maeda, Y., Inamoto, Y., Okada, M., Maki, A., Shimada, F., Tajima, T., Wroclawska, M., Zeiser, R., & Onizuka, M. (2024). Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03772-6
Vancouver
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, et al. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03772-6
BibTeX
@article{Teshima2024,
author = {Teshima, Takanori and Onishi, Yasushi and Kato, Koji and Taniguchi, Shuichi and Miyamura, Koichi and Fukushima, Kentaro and Kato, Jun and Ishikawa, Takayuki and Doki, Noriko and Nakamae, Hirohisa and Maeda, Yoshinobu and Inamoto, Yoshihiro and Okada, Masaya and Maki, Akio and Shimada, Fumika and Tajima, Takeshi and Wroclawska, Monika and Zeiser, Robert and Onizuka, Makoto},
title = {Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03772-6}
}
EUVIMED